lumbar regressive disease
Conditions
Interventions
treatment group:celecoxib combined with gabapentin oralled
control group:blank control
Sponsors
Department of Orthopaedics, Zhujiang Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) surgery is under the same group of doctors according to the same standard; (2) patients aged 18~75years, body mass index <30 kg / m2; (3) patients are American Society of Anesthesiologists physical statuses I-II and agreed to participate in this clinical trial.
Exclusion criteria
Exclusion criteria: (1) infectious inflammation, diabetes, cancer, immune and hematological disorders and chronic inflammatory disease patients; (2) severe osteoporosis; (3) follow-up information is incomplete or is less than 1 week; (4) infection, Internal fixation screw shedding, lower limb deep vein thrombosis or other complications during the hospitalization or follow-up affecting the rehabilitation process; (5) prior use of the investigated medications or any non-steroidal anti-inflammatory drugs (NSAIDs) 4 week ago, contraindication to morphine or investigated medications, or current use of anticoagulants or antiplatelet medication; (6) history of lumbar surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| skin temperature;VAS score; | — |
Secondary
| Measure | Time frame |
|---|---|
| the extra press of PCA analgesic pump;tramadol requirements;WBC;HGB;ESR;CRP; postoperative complications; | — |
Countries
China
Contacts
Public ContactLixin Zhu
Department of Orthopaedics, Zhujiang Hospital, Southern Medical University
Outcome results
None listed